Your browser doesn't support javascript.
loading
Kinetics of pre-myelodysplastic syndromes blood values correlate with disease risk and survival.
Joffe, Erel; Greenbaum, Uri; Man-El, Gili; Filanovsky, Kalman; Oster, Howard S; Levi, Itai; Raanani, Pia; Avivi, Irit; Mittelman, Moshe.
Afiliação
  • Joffe E; Sackler School of Medicine, Tel-Aviv University, Tel Aviv, Israel.
  • Greenbaum U; Memorial Sloan Kettering Cancer Center, Department of Medicine, New York City, New York, USA.
  • Man-El G; Department of Medicine, Weill Cornell College of Medicine, New York City, New York, USA.
  • Filanovsky K; Ben-Gurion University of the Negev, School of Medicine, Beer-Sheva, Israel.
  • Oster HS; Department of Medicine, Soroka Medical Center, Beer-Sheva, Israel.
  • Levi I; Sackler School of Medicine, Tel-Aviv University, Tel Aviv, Israel.
  • Raanani P; The Hebrew University, School of Medicine, Jerusalem, Israel.
  • Avivi I; Department of Medicine, Kaplan Medical Center, Rehovot, Israel.
  • Mittelman M; Sackler School of Medicine, Tel-Aviv University, Tel Aviv, Israel.
Hematol Oncol ; 38(5): 782-791, 2020 Dec.
Article em En | MEDLINE | ID: mdl-32632931
We reviewed pre-diagnosis clinical data of 420 patients with pathologically confirmed myelodysplastic syndromes (MDSs) presenting with anemia. In 232 patients with yearly pre-diagnosis complete blood counts (CBCs), we also analyzed CBC kinetics in respects to a standardized timepoint in which all patients had similar levels of hemoglobin (Hgb). At the standardized timepoint (last documented 12 > Hgb ≥ 11 g/dL), occurring months-years before diagnosis, median CBC values were Hgb 11.4 g/dL, absolute neutrophil count (ANC) 2.7 × 103 (k)/mcl, and platelets (PLTs) 181 k/mcl. Gradual changes in CBC could be observed years prior to this timepoint, for the most part while within normal/near-normal limits. During this time, most patients had a coexisting alternative etiology for anemia. Patients with high-risk cytogenetic/blast features had a rapid and steeper decrease in counts in the last year before developing a concerning anemia (decrease in: Hgb 0.75 g/dL vs 0.55 g/dL; PLT 29.5 vs 4.5 k/mcl; ANC 0.86 vs 0.4 k/mcl, P = .03). Low-risk patients had a high rate of longstanding mild anemia (31% vs 16%, P = .05). Rate of development of cytopenia and number of involved hematopoietic lines were prognostic. In 65% of patients, with near normal CBC at the standardized timepoint, but in whom there was a decrease in multiple hematopoietic lines over the preceding year, the 5-year overall survival (5yOS) was 53% compared to 71% in patients with isolated slowly progressing anemia (20% of patients). In 15% of patients with mild cytopenia developing after both a rapid decrease and multiple involved lines, prognosis was dismal (5yOS 34%). In conclusion, kinetics of pre-MDS CBC values correlate with disease risk and survival.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Síndromes Mielodisplásicas / Biomarcadores Tipo de estudo: Diagnostic_studies / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Hematol Oncol Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Israel

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Síndromes Mielodisplásicas / Biomarcadores Tipo de estudo: Diagnostic_studies / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Hematol Oncol Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Israel